Our influential research and analysis attracts the attention of leading publishers every day.

Valeant Pharmaceuticals, Novartis and Mylan are circling Actavis, the world’s third largest generics manufacturer, for acquisition, but will anyone be able to afford the record-breaking price tag?

Takeda’s recently announced positive late-stage results for new type 2 diabetes drug, fasiglifam, has prompted excitement within the industry and raised hopes of reviving Takeda’s diabetes treatment business, following last year’s patent expiration of hit product Actos. But as drugs continue to imp

The expansion of the insured population, prompted by the introduction of Patient Protection and Affordable Care Act (PPACA), will play a key role in driving US pharmaceutical market revenue up by a third by the end of the decade.

High potential as a combination therapy and a better safety profile will see Arena’s new obesity drug Belviq surpass Vivus’ challenger Qsymia in the near-term battle to become the market’s dominant treatment, predicts an analyst with research and consulting firm GlobalData.

While the risks involved in HIV vaccine development have turned Big Pharma away from pursuing a preventative vaccine, government-funded organizations and smaller biotech firms may provide the answer, a GlobalData analyst has said in a research note as World AIDS Vaccine Day approaches.

The introduction of new hepatitis C (HCV) drugs in the second half of 2013 will result in a significant increase in annual treatment costs and can lead to insurers slashing the number of patients eligible for coverage.

Italian pharmaceutical market value will continue to fall in the foreseeable future, due to government support of generics and a stringent drug pricing policy.

Bucking a global trend of falling revenues, weak penetration of generic drugs and an increasing patient population will ensure steady growth of Japan’s Chronic Myeloid Leukemia (CML) market over the next decade.

With the Affordable Care Act (ACA) now covering a range of preventative services within the women’s health sector, major generics manufacturers are taking key steps to ensure they maximize profits in a newly promising market.

The rising prices of new cancer drugs are resulting in an increasing cost burden for patients and healthcare systems that does not necessarily correlate with the survival benefit the drug provides, and which is driving the rapid transition to generics and limiting the use of new market entrants.